Zacks Investment Research
18 Nov 2026, 16:45 UTC · 2h ago
NVS Gets FDA Nod for Cosentyx in Adults With Polymyalgia Rheumatica
Impact · against what's priced in
Novartis gains a modest catalyst from the FDA approval of Cosentyx for polymyalgia rheumatica, expanding the drug's reach to a US population of 966,000. The strong phase III data, showing a 20 percentage point remission delta over placebo, supports a premium pricing strategy for this new indication.
- NVS+0.60
No priced-in read yet
- In context
The FDA approval for Cosentyx in treating adults with polymyalgia rheumatica adds an 11th indication and introduces a first-in-class biologic for a patient population of 966,000 in the US.
Read from the article alone

Top 1 mover · tap to explore




